Article
Characterization of the impact of daclizumab beta on circulating natural killer cells by mass cytometry
2019-12-05
Abstract excerpt
Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56 bright subpopulation of NK cells that is correlated with the drug’s therapeutic effects. As NK cells represent a heterogeneous population of lymphocytes with...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bd3a3c77-09f3-50b1-bc80-3f79bc5dbf62
- DOI
- 10.1101/865477
